Impact Factor
3.76
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
4.16
836 total citations
h5-index
34
h5 depth signal
Cited share
86.0%
178 of 207
Total citations
836
Citation footprint
Metric signal
3.55
External metric anchor
Self-citation
7.7%
64 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
284
United Kingdom
148
Canada
137
Netherlands
133
France
124
Citing Fields of Research
Musculoskeletal Disorders
647
Neuromuscular Disorders
287
Nervous System Disorders
150
Physiology
82
Neurodegenerative Disorders
46
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
1,035
Articles tracked across the journal lifetime
Indexed publication set
207
178 cited publications
Last 12 months
136
11.3 publications/month
Open access share
100.0%
136 OA publications in the last year
Leading citing country
United States
284 citing publications
Leading citing field
Musculoskeletal Disorders
647 citing publications
Latest tracked publication
17 October 2026
10 recent records available
Coverage & Indexing History
v3n1, 2016-
v3n1, 2016- ; Selected citations only before this date
Active Coverage
Research Focus & Classification
Indexed Subjects
Musculoskeletal Disorders
Neuromuscular Disorders
Broad Categories
Neurology
Musculoskeletal Disorders
MeSH Descriptors
Neuromuscular Diseases
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1177/22143602261488135
Open DOI
Neurofilaments in cerebrospinal fluid and/or serum as a possible biomarker of pediatric spinal muscular atrophy
Background: Spinal muscular atrophy (SMA) is a severe, genetically determined neuromuscular disorder characterised by progressive muscle weakness resulting from motor neuron degeneration. Although therapies such as nusinersen have altere...
02
DOI 10.1177/22143602261494687
Open DOI
The cognitive-behavioral missing link in myotonic dystrophy type 1: Rethinking social cognition assessment
Background: Myotonic dystrophy type 1 (DM1) is associated with central nervous system involvement and cognitive–behavioral alterations, including deficits in social cognition. However, standard neuropsychological assessments based on acc...
03
DOI 10.1177/22143602261486896
Open DOI
Managing growth and puberty concerns in individuals with Duchenne muscular dystrophy: Updated guidance and future directions
Long-term glucocorticoid therapy is standard of care for individuals with Duchenne muscular dystrophy (DMD) but often results in impaired growth and delayed or incomplete puberty, impacting their physical and psychosocial health. Althoug...
04
DOI 10.1177/22143602261491510
Open DOI
Combined qualitative and quantitative MRI reveals short-term progression in facioscapulohumeral muscular dystrophy
Facioscapulohumeral muscular dystrophy (FSHD) is characterized by slowly progressive and heterogeneous muscle involvement; therefore, clinical measures show limited sensitivity to short-term change. Magnetic resonance imaging (MRI) provi...
05
DOI 10.1177/22143602261493651
Open DOI
An international patient survey of RYR1-related diseases: The patient perspective on clinical trial participation
Background and objective: RYR1 -related diseases ( RYR1 -RD) are a group of genetic conditions characterized by early-onset muscle weakness, causing functional impairments. An increasing number of clinical trials is on the horizon. This ...
06
DOI 10.1177/22143602261485046
Open DOI
Adrenal insufficiency in individuals with Duchenne muscular dystrophy treated with glucocorticoids: Insights from the past, current challenges, and future directions
Duchenne muscular dystrophy (DMD) is an X-linked recessive dystrophinopathy characterized by progressive loss of muscle strength, respiratory insufficiency, cardiac dysfunction, and premature death. Despite a rapidly evolving therapeutic...
07
DOI 10.1177/22143602261481269
Open DOI
Delving into the clinical and genetic spectrum of NLSDM: A case study
Mutations in the PNPLA2 gene, which encodes adipose triglyceride lipase (ATGL), are linked to neutral lipid storage disease with myopathy (NLSDM). This rare genetic disorder is marked by abnormal accumulation of neutral lipids in cytopla...
08
DOI 10.1177/22143602261485644
Open DOI
Cramps as the initial presentation of CANVAS/RFC1-related disorder
Biallelic mutations in the RFC1 gene are associated with CANVAS syndrome (cerebellar ataxia, neuropathy and vestibular areflexia). Peripheral nerve involvement in the form of sensory neuronopathy and small fiber autonomic axonopathy is a...
09
DOI 10.1177/22143602261481647
Open DOI
Report on the 7th Ottawa International Conference on Neuromuscular Disease & Biology – September 11‐13, 2025, Ottawa, Canada
The 7th Ottawa International Conference on Neuromuscular Disease and Biology was held on September 11-13, 2025, in Ottawa, Canada. The conference brought together international experts in neuromuscular disease, biology and clinical care ...
10
DOI 10.1177/22143602261488126
Open DOI
X-linked myotubular myopathy, liver disease, and gene therapy
X-linked myotubular myopathy (XLMTM) is a rare and severe neuromuscular disorder commonly characterized by profound skeletal muscle weakness, significant co-morbid disabilities, and early death. XLMTM has traditionally been viewed as pri...
Bibliographical & Catalog Notes
Also issued online.